We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Compared to Estimates, AbbVie (ABBV) Q2 Earnings: A Look at Key Metrics
Read MoreHide Full Article
AbbVie (ABBV - Free Report) reported $13.87 billion in revenue for the quarter ended June 2023, representing a year-over-year decline of 4.9%. EPS of $2.91 for the same period compares to $3.37 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $13.52 billion, representing a surprise of +2.54%. The company delivered an EPS surprise of +4.30%, with the consensus EPS estimate being $2.79.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how AbbVie performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Net Revenue- Venclexta- US: $265 million versus $285.11 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +4.7% change.
Net Revenue- Venclexta- International: $306 million versus $270.75 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +21.4% change.
Net Revenue- Imbruvica- International: $241 million versus $231.17 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -14.8% change.
Net Revenue- Imbruvica- US: $666 million versus the five-analyst average estimate of $643.41 million. The reported number represents a year-over-year change of -22.7%.
Net Revenue- Mavyret: $387 million versus $364.05 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -2.8% change.
Net Revenue- Lumigan/Ganfort: $119 million versus the five-analyst average estimate of $126.20 million. The reported number represents a year-over-year change of -8.5%.
Net Revenue- Ubrelvy- Total: $196 million versus $202.37 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +6% change.
Net Revenue- Hematologic Oncology- Total: $1.48 billion versus $1.43 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -10.4% change.
Net Revenue- Immunology- Total: $6.81 billion versus $6.60 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -5.5% change.
Net Revenue- Other Neuroscience- Total: $70 million compared to the $57.48 million average estimate based on five analysts. The reported number represents a change of -53.3% year over year.
Net Revenue- Other Aesthetics- Total: $331 million versus $316.15 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -0.3% change.
Net Revenue- Aesthetics- Total: $1.38 billion versus $1.33 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +1% change.
Shares of AbbVie have returned +7.1% over the past month versus the Zacks S&P 500 composite's +5.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Compared to Estimates, AbbVie (ABBV) Q2 Earnings: A Look at Key Metrics
AbbVie (ABBV - Free Report) reported $13.87 billion in revenue for the quarter ended June 2023, representing a year-over-year decline of 4.9%. EPS of $2.91 for the same period compares to $3.37 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $13.52 billion, representing a surprise of +2.54%. The company delivered an EPS surprise of +4.30%, with the consensus EPS estimate being $2.79.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how AbbVie performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Net Revenue- Venclexta- US: $265 million versus $285.11 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +4.7% change.
- Net Revenue- Venclexta- International: $306 million versus $270.75 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +21.4% change.
- Net Revenue- Imbruvica- International: $241 million versus $231.17 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -14.8% change.
- Net Revenue- Imbruvica- US: $666 million versus the five-analyst average estimate of $643.41 million. The reported number represents a year-over-year change of -22.7%.
- Net Revenue- Mavyret: $387 million versus $364.05 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -2.8% change.
- Net Revenue- Lumigan/Ganfort: $119 million versus the five-analyst average estimate of $126.20 million. The reported number represents a year-over-year change of -8.5%.
- Net Revenue- Ubrelvy- Total: $196 million versus $202.37 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +6% change.
- Net Revenue- Hematologic Oncology- Total: $1.48 billion versus $1.43 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -10.4% change.
- Net Revenue- Immunology- Total: $6.81 billion versus $6.60 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -5.5% change.
- Net Revenue- Other Neuroscience- Total: $70 million compared to the $57.48 million average estimate based on five analysts. The reported number represents a change of -53.3% year over year.
- Net Revenue- Other Aesthetics- Total: $331 million versus $316.15 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -0.3% change.
- Net Revenue- Aesthetics- Total: $1.38 billion versus $1.33 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +1% change.
View all Key Company Metrics for AbbVie here>>>Shares of AbbVie have returned +7.1% over the past month versus the Zacks S&P 500 composite's +5.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.